Chemours Co (NYSE:CC) Shares Acquired by NEXT Financial Group Inc

NEXT Financial Group Inc increased its stake in Chemours Co (NYSE:CC) by 2.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 93,160 shares of the specialty chemicals company’s stock after acquiring an additional 2,351 shares during the quarter. NEXT Financial Group Inc owned approximately 0.06% of Chemours worth $1,392,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. DNB Asset Management AS boosted its position in Chemours by 21.6% during the third quarter. DNB Asset Management AS now owns 641,890 shares of the specialty chemicals company’s stock valued at $9,590,000 after purchasing an additional 114,139 shares during the last quarter. Boenning & Scattergood Inc. lifted its position in shares of Chemours by 3.2% in the third quarter. Boenning & Scattergood Inc. now owns 37,576 shares of the specialty chemicals company’s stock worth $561,000 after buying an additional 1,160 shares during the last quarter. Rothschild Investment Corp IL lifted its position in shares of Chemours by 121.0% in the third quarter. Rothschild Investment Corp IL now owns 20,837 shares of the specialty chemicals company’s stock worth $311,000 after buying an additional 11,410 shares during the last quarter. Pacer Advisors Inc. lifted its position in shares of Chemours by 9,563.8% in the third quarter. Pacer Advisors Inc. now owns 58,756 shares of the specialty chemicals company’s stock worth $878,000 after buying an additional 58,148 shares during the last quarter. Finally, AI Financial Services LLC lifted its position in shares of Chemours by 18.0% in the third quarter. AI Financial Services LLC now owns 90,640 shares of the specialty chemicals company’s stock worth $1,354,000 after buying an additional 13,829 shares during the last quarter. Institutional investors and hedge funds own 79.81% of the company’s stock.

A number of research firms have recently commented on CC. ValuEngine upgraded Chemours from a “sell” rating to a “hold” rating in a research note on Wednesday, October 2nd. TheStreet lowered Chemours from a “b-” rating to a “c+” rating in a research note on Friday, August 9th. BMO Capital Markets lowered their price target on Chemours from $31.00 to $23.00 and set an “outperform” rating on the stock in a research note on Monday, September 9th. Susquehanna Bancshares upgraded Chemours from a “neutral” rating to a “positive” rating and lowered their price target for the company from $37.00 to $18.00 in a research note on Tuesday, August 20th. Finally, Argus lowered Chemours from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $29.77.

Shares of CC opened at $15.15 on Friday. Chemours Co has a 12-month low of $11.71 and a 12-month high of $41.60. The company has a quick ratio of 1.09, a current ratio of 1.96 and a debt-to-equity ratio of 5.37. The firm has a market capitalization of $2.47 billion, a price-to-earnings ratio of 2.67, a P/E/G ratio of 0.40 and a beta of 2.57. The stock’s 50-day moving average price is $14.80 and its 200 day moving average price is $22.08.

Chemours (NYSE:CC) last released its quarterly earnings data on Thursday, August 1st. The specialty chemicals company reported $0.72 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.18). Chemours had a net margin of 10.33% and a return on equity of 71.90%. The company had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter in the prior year, the company posted $1.71 earnings per share. The company’s revenue for the quarter was down 22.5% on a year-over-year basis. Equities research analysts expect that Chemours Co will post 2.45 EPS for the current year.

In other Chemours news, COO Mark Newman bought 20,000 shares of Chemours stock in a transaction dated Wednesday, September 11th. The shares were acquired at an average cost of $16.42 per share, with a total value of $328,400.00. Following the acquisition, the chief operating officer now directly owns 114,261 shares of the company’s stock, valued at $1,876,165.62. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mary B. Cranston bought 1,790 shares of Chemours stock in a transaction dated Wednesday, August 7th. The stock was acquired at an average cost of $13.99 per share, for a total transaction of $25,042.10. The disclosure for this purchase can be found here. Over the last quarter, insiders bought 53,790 shares of company stock worth $799,332. Corporate insiders own 2.34% of the company’s stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.

Featured Article: What is a stock buyback?

Institutional Ownership by Quarter for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.